< Back to previous page
Researcher
Marc Ferrante
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Feb 2004 → Today
Projects
1 - 10 of 16
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model informed Dosage optimization of Crizanlizumab for the management of Sickle Cell Disease in TanzaniaFrom17 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding and treating symptom burden in inflammatory bowel diseases: a psychological perspectiveFrom1 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The gut barrier as master regulator of microbiome-host interactions: exploring the structure and function of paracellular and transcellular transport in the large intestine.From1 Oct 2021 → TodayFunding: BOF - various, BOF - projects
- From drug development to registration: optimalization of flow processesFrom10 Feb 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Advanced 3D Complex Tissues BioAssembly Platform for Precision Disease Modeling, Drug Discovery and Regenerative Medicine (3D-BioBOT)From1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- H2O Health Outcomes ObservatoryFrom1 Oct 2020 → TodayFunding: H2020 - Health, demographic change and wellbeing
- OrganID: Organ-derived complex 2D/3D cultures in human diseaseFrom1 Oct 2020 → TodayFunding: FWO Strategic Basic Research (SBO)
- LONG-TERM SEQUENTIAL USE OF BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: HARMLESS OR HAZARDOUS?From1 Aug 2017 → 24 Sep 2021Funding: FWO fellowships
- Predicting response to treatment in patients with inflammatory bowel diseaseFrom1 Jan 2017 → 31 Dec 2022Funding: Foreign private sponsor - undefined
Publications
1 - 10 of 476
- Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies(2024)
Authors: Bram Verstockt, Marc Ferrante, Séverine Vermeire
- Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1007 - 1008 - Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.(2024)
Authors: Marc Ferrante
Pages: 121 - Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial(2024)
Authors: Marc Ferrante
Pages: 416 - 423 - Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 723 - 724 - Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.(2024)
Authors: Bram Verstockt, Marc Ferrante, João Guedelha Sabino, Jeroen Raes, Séverine Vermeire
Pages: 483 - 495 - IDH1-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated-type dysplasia.(2024)
Authors: Gert De Hertogh, Marc Ferrante
Pages: 515 - 524 - Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study(2024)
Authors: Dahham Alsoud, João Guedelha Sabino, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
- Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study(2024)
Authors: Jo Swinnen, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
- The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1 - 7
Patents
1 - 5 of 5
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)